Ragbourne Sophie C, Crook Martin A
Department of Clinical Biochemistry and Metabolic Medicine, Guy's Hospital, London, UK.
Department of Clinical Biochemistry and Metabolic Medicine, Guy's Hospital, London, UK.
Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):340-346. doi: 10.1016/j.clml.2017.05.004. Epub 2017 May 10.
Since its introduction more than 50 years ago, hematopoietic stem-cell transplantation (HSCT) has transformed from an inescapably fatal procedure to one where cure from malignant and other nonmalignant hematologic diseases is becoming increasingly common. Nevertheless, longevity is not entirely restored. New causes of mortality have emerged; of particular importance is that of increased cardiovascular disease (CVD), related to metabolic syndrome and its components. Controversy exists over whether the metabolic abnormalities induced are a direct effect of HSCT itself or a consequence of other therapies involved. Analysis of the mechanisms that promote the changes in metabolic components will give insight into future HSCT therapy as well as CVD pathogenesis and prevention.
自50多年前引入以来，造血干细胞移植（HSCT）已从一种必然致命的手术转变为一种治愈恶性和其他非恶性血液疾病日益常见的手术。然而，寿命并未完全恢复。新的死亡原因出现了；特别重要的是与代谢综合征及其组成部分相关的心血管疾病（CVD）增加。关于诱导的代谢异常是HSCT本身的直接作用还是所涉及的其他疗法的结果存在争议。对促进代谢成分变化的机制进行分析将有助于深入了解未来的HSCT治疗以及CVD的发病机制和预防。
